Cargando…

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial

PURPOSE: Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in l...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Susanne M., Kudrimoti, Mahesh, Dressler, Emily V., Gleason, John F., Silver, Natalie L., Regine, William F., Valentino, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514161/
https://www.ncbi.nlm.nih.gov/pubmed/28740895
http://dx.doi.org/10.1016/j.adro.2016.06.003
_version_ 1783250793690824704
author Arnold, Susanne M.
Kudrimoti, Mahesh
Dressler, Emily V.
Gleason, John F.
Silver, Natalie L.
Regine, William F.
Valentino, Joseph
author_facet Arnold, Susanne M.
Kudrimoti, Mahesh
Dressler, Emily V.
Gleason, John F.
Silver, Natalie L.
Regine, William F.
Valentino, Joseph
author_sort Arnold, Susanne M.
collection PubMed
description PURPOSE: Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN). EXPERIMENTAL DESIGN: Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m(2)) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity. RESULTS: A total of 24 evaluable patients were enrolled. Primary sites included oropharynx (62.5%), larynx (20.8%), oral cavity (8.3%), and hypopharynx (8.3%). Grade 3/4 toxicities included neutropenia (20%), leukopenia (32%), dehydration/hypotension (8%), anemia (4%), infection (4%), pulmonary/allergic rhinitis (4%), and diarrhea (4%). Primary site response rate was 23/24 (95.8%): 15/24 (62.5%) complete response, 8/24 (33.3%) partial response, and 1/24 (4.2%) stable disease. With median follow-up of 7.75 years, 9-year rates for overall survival were 49.4% (95% confidence interval [CI], 30.5-79.9), PFS was 72.2% (CI, 55.3-94.3), and disease-specific survival was 65.4% (44.3-96.4). CONCLUSION: Chemopotentiating LDFRT combined with paclitaxel and carboplatin is effective in SCCHN and provided an excellent median overall survival of 107.2 months, with median PFS not yet reached in this locally advanced SCCHN cohort. This compares favorably to prior investigations and caused fewer grade 3 and 4 toxicities than more intensive, 3-drug induction regimens. This trial demonstrates the innovative use of LDFRT as a potentiator of chemotherapy.
format Online
Article
Text
id pubmed-5514161
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55141612017-07-24 Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Arnold, Susanne M. Kudrimoti, Mahesh Dressler, Emily V. Gleason, John F. Silver, Natalie L. Regine, William F. Valentino, Joseph Adv Radiat Oncol Scientific Article PURPOSE: Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN). EXPERIMENTAL DESIGN: Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m(2)) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity. RESULTS: A total of 24 evaluable patients were enrolled. Primary sites included oropharynx (62.5%), larynx (20.8%), oral cavity (8.3%), and hypopharynx (8.3%). Grade 3/4 toxicities included neutropenia (20%), leukopenia (32%), dehydration/hypotension (8%), anemia (4%), infection (4%), pulmonary/allergic rhinitis (4%), and diarrhea (4%). Primary site response rate was 23/24 (95.8%): 15/24 (62.5%) complete response, 8/24 (33.3%) partial response, and 1/24 (4.2%) stable disease. With median follow-up of 7.75 years, 9-year rates for overall survival were 49.4% (95% confidence interval [CI], 30.5-79.9), PFS was 72.2% (CI, 55.3-94.3), and disease-specific survival was 65.4% (44.3-96.4). CONCLUSION: Chemopotentiating LDFRT combined with paclitaxel and carboplatin is effective in SCCHN and provided an excellent median overall survival of 107.2 months, with median PFS not yet reached in this locally advanced SCCHN cohort. This compares favorably to prior investigations and caused fewer grade 3 and 4 toxicities than more intensive, 3-drug induction regimens. This trial demonstrates the innovative use of LDFRT as a potentiator of chemotherapy. Elsevier 2016-07-14 /pmc/articles/PMC5514161/ /pubmed/28740895 http://dx.doi.org/10.1016/j.adro.2016.06.003 Text en © 2016 The Authors on behalf of the American Society for Radiation Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Arnold, Susanne M.
Kudrimoti, Mahesh
Dressler, Emily V.
Gleason, John F.
Silver, Natalie L.
Regine, William F.
Valentino, Joseph
Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title_full Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title_fullStr Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title_full_unstemmed Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title_short Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial
title_sort using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: results of a prospective phase 2 trial
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514161/
https://www.ncbi.nlm.nih.gov/pubmed/28740895
http://dx.doi.org/10.1016/j.adro.2016.06.003
work_keys_str_mv AT arnoldsusannem usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT kudrimotimahesh usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT dressleremilyv usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT gleasonjohnf usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT silvernataliel usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT reginewilliamf usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial
AT valentinojoseph usinglowdoseradiationtopotentiatetheeffectofinductionchemotherapyinheadandneckcancerresultsofaprospectivephase2trial